- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02438761
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
Phase II Evaluating the Efficacy of the Dual Inhibition of Phosphoinositide 3 Kinase (PI3K)/Akt /Mammalian Target Of Rapamycine (mTOR) Signaling Pathway by PF-05212384 (PKI-587) for Patients With Myeloid Neoplasm Secondary to Chemo-radiotherapy (t-AML/MDS) or de Novo Relapsed or Refractory AML.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression.
Blood tests (hemogram) are assessed weekly before each injection of PF-05212384 (PKI-587). Bone marrow aspiration (myelogram) is performed to evaluate the response before starting treatment and before the start of cycle 3 (after two cycles) and at the end of the study (after four cycles). Good responders who continue treatment after four cycles will be evaluated by bone marrow aspiration (myelogram) every two cycles and after the end of treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ile De France
-
Paris, Ile De France, France, 75475
- Hôpital Saint-Louis
-
Paris, Ile De France, France, 75679
- Hopital Cochin
-
Saint-Cloud, Ile De France, France, 92210
- Institut Curie - Hôpital René Huguenin
-
-
Midi-Pyrénées
-
Toulouse, Midi-Pyrénées, France, 31059
- CHU de Toulouse
-
-
Paca
-
Marseille, Paca, France, 13009
- Institut Paoli Calmette
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients belong to one of three categories:
- Myeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) aged 60 and over with unfavorable cytogenetics (European Leukemia Network definition 2010), the first cancer must have been in remission for more than two years, except in situ carcinoma, basal cell carcinoma and squamous cell carcinoma
- Relapsed or refractory de novo AML aged 18 and over (multiple relapses allowed), regardless of the risk group, provided not being eligible for allogeneic bone marrow transplantation
- de novo AML at diagnosis, aged 60 and over and considered unfit to benefit from induction chemotherapy associated with aplasia (at the discretion of the investigator)
- Adequate glycemic balance defined by glycated hemoglobin ≤ 8%
- Females of childbearing potential (FCBP) should receive effective contraception: a negative pregnancy blood test is required within 2 weeks before starting experimental treatment.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2
- Absence of severe or active infection
- Adequate systolic cardiac function : Left Ventricular Ejection Fraction (LVEF) ≥ 50%
- Adequate hepatic function: Aspartate Aminotransferase Test (AST) and Alanine Aminotransferase Test (ALT) ≤ 3 times the upper limit of normal (ULN), bilirubin ≤ 1.5 x ULN
- Adequate renal function: serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance > 60 ml/min.
- Signed informed consent
Exclusion Criteria:
- Glucose intolerance or diabetes mellitus, treated or untreated
- First cancer in evolution(solid tumor or lymphoma) or in remission for less than two years, except in situ carcinoma, basal cell carcinoma and squamous cell carcinoma
- AML secondary to MDS or myeloproliferative syndrome (WHO 2008 definitions)
- Acute Promyelocytic Leukaemia (APL or AML French American British (FAB) classification 3) de novo or secondary to treatment (t-APL)
- de novo or secondary Core Binding Factor (CBF)/AML
- de novo or secondary Philadelphia Chromosome (Ph) 1 positive AML defined by the presence of a t(9.22) or a Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog (BCR-ABL) transcript
- Leukocytes above 30.000/mm3 (30 G/L) at enrollment
- Antileukemic treatment within 15 days before enrollment, with the exception of hydroxyurea
- Central nervous system leukemic involvement
- Pregnant or lactating women, or women of childbearing potential without effective contraception
- Prior history of allogeneic bone marrow transplantation
- Prior history of organ transplantation or other cause of severe or chronic immunodeficiency Human
- Seropositivity for Human Immunodeficiency Virus (HIV) or Human T-Lymphotropic Virus-1 (HTLV-1) viruses, active B or C hepatitis
- Inclusion in another experimental anti-cancer clinical trial*
- Patients unable to undergo medical monitoring for geographical, social or psychological issues
- Patient under measure of legal protection
No social security
- For ethical reasons, the exclusion period before considering the possibility of participating in another clinical study with a new experimental molecule cannot be determined, yet each case will be discussed on an individual basis with the study coordinator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PF-05212384
150 mg Intra-venous every week
|
PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy of PF-05212384
Time Frame: 4 months after treatment
|
The overall response rate will be assessed according to the International Working Group (IWG) AML and MDS criteria (by B.D. Cheson).
|
4 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerance and toxicity during treatment
Time Frame: 4 months
|
Issued the Common Terminology Criteria for Adverse Events (CTCAE) version 4 National Cancer Institute (NCI)
|
4 months
|
Treatment compliance
Time Frame: 4 months
|
Treatment compliance will be assessed by the ratio between the number of cycles administered on the expected number of cycles, and on time between treatment cycles
|
4 months
|
Progressive Free Survival (PFS)
Time Frame: one year
|
Progressive Free Survival at one year from the date of inclusion to the date of progression of the disease or death
|
one year
|
Overall survival
Time Frame: 48 months
|
Overall Survival from the date of inclusion to the date of death
|
48 months
|
Evaluation of Quality of life
Time Frame: 4 months
|
Quality of life (QLQ-C30) questionnaire according to European Organisation for Research and Treatment of Cancer (EORTC)
|
4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jacques Vargaftig, MD, Institut Curie - Hôpital René Huguenin
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IC 2014-10 LAM-PIK
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia, in Relapse
-
University of FreiburgCompletedAcute Myeloid Leukemia, in RelapseGermany
-
UNC Lineberger Comprehensive Cancer CenterMerck Sharp & Dohme LLCActive, not recruitingAcute Myeloid Leukemia, in RelapseUnited States
-
St. Jude Children's Research HospitalAbbVie; Gateway for Cancer Research; Karyopharm Therapeutics IncRecruitingRefractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Leukemia of Ambiguous Lineage in Relapse | Refractory Acute Leukemia of Ambiguous LineageUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid LeukemiaUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
All India Institute of Medical Sciences, New DelhiUnknown
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Bio-Path Holdings, Inc.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
Clinical Trials on PF-05212384
-
PfizerCompleted
-
Dana-Farber Cancer InstitutePfizerRecruitingPancreatic Cancer | Solid Tumors | Lung Cancer Squamous Cell | Head & Neck CancerUnited States
-
PfizerCompletedNeoplasmsUnited States, Spain, United Kingdom
-
PfizerTerminatedEndometrial NeoplasmsUnited States, Canada, Spain, United Kingdom, Japan, Russian Federation, Poland, Australia
-
PfizerTerminatedAdvanced CancerItaly, United States, Canada, Spain
-
PfizerCompletedNeoplasmUnited States, Spain, Canada, Italy, United Kingdom
-
Cristiana SessaCompletedBreast Cancer | NSCLC | Endometrial Cancer | Ovary Cancer | Small Cell Lung Cancer (SCLC) | Head and Neck (HNSCC)Switzerland
-
PfizerTerminatedMetastatic Colorectal CarcinomaUnited States, Canada, Spain
-
PfizerTerminatedMetastatic Colorectal CancerKorea, Republic of, United States, Japan, Spain